Format

Send to

Choose Destination
Vaccine. 2010 Apr 26;28(19):3285-90. doi: 10.1016/j.vaccine.2010.02.104. Epub 2010 Mar 10.

The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection.

Author information

1
Department of Epidemiology and Preventive Health, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel. prendi@post.tau.ac.il

Abstract

This study was undertaken to estimate the magnitude of Bordetella pertussis infections in a highly vaccinated population in Israel in order to evaluate the relationship between clinical notification data and serology-based evidence of infection. A cross-sectional survey was conducted on a total of 1982 serum samples from the National Serum Bank, collected from January 2000 through December 2001, in order to monitor high levels of pertussis toxin (PT) IgG antibody indicative of recent B. pertussis infection, by standardized methods. The estimation yielded an infection incidence rate of 2448 per 100,000 population (> or =3 years of age) for the year 2000 compared to an annual incidence of reported pertussis of 5.6 per 100,000 for the same period. The peaks of estimated incidence of infection were found in the groups of 15-19-year olds (5245 per 100,000) and older than 60 years (6469 per 100,000), whereas the majority of clinical pertussis cases were reported for the 10-14-year olds (20.5 per 100,000). The findings clearly show that despite a high vaccination coverage rate (>93%), there is still a considerable circulation of B. pertussis, particularly in adolescents and elderly. Population-based serosurveillance for pertussis offers the potential to assist interpretation of trends independent of notification and diagnostic bias.

PMID:
20226250
DOI:
10.1016/j.vaccine.2010.02.104
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center